Developing the next generation of oncology therapies for patients.
Location: United States
Employees: 1-10
Total raised: $210M
Investors 5
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| 27.05.2024 | Sofinnova ... | sofinnova.... |
| 30.08.2023 | OrbiMed | orbimed.co... |
| 05.07.2025 | INCE Capit... | incecap.co... |
| 06.06.2023 | SR One | srone.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 02.10.2025 | Series B | $60M | New Enterp... |
| 27.03.2024 | Series A | $150M | - |
Mentions in press and media 14
| Date | Title | Description |
| 03.10.2025 | Avenzo Therapeutics Secures $60 Million Series B to Advance Oncology Breakthroughs | Avenzo Therapeutics secured $60 million in Series B funding. This propels their oncology pipeline. The San Diego biotech now totals $446 million raised. OrbiMed and SR One led the round. New investor Longwood Fund joined. Key existing backe... |
| 02.10.2025 | INCE Capital Portfolio Company Avenzo Therapeutics Announces $60 Million Series B Financing | INCE Capital portfolio company, Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, announced the closing of a $60 million Series B financing on September 22, 2025. Th... |
| 22.09.2025 | Avenzo Therapeutics Announces $60M Series B Financing | SAN DIEGO, CA, Avenzo Therapeutics, a clinical-stage biotechnology company, announced the closing of a $60 million Series B financing. >> Click here for more funding data on Avenzo Therapeutics >> To export Avenzo Therapeutics ... |
| 22.09.2025 | Avenzo Therapeutics Raised $60M in Series B Funding | Avenzo Therapeutics, a San Diego, CA-based clinical-stage biotechnology company developing new oncology therapies, raised $60M in Series B funding. The round was led by OrbiMed and SR One, with participation from new investor Longwood Fund,... |
| 09.07.2025 | First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 | SHANGHAI, July 9, 2025 /PRNewswire/ -- Duality Biotherapeutics' ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapie... |
| 07.01.2025 | Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate | Avenzo to receive exclusive global license (excluding Greater China) for development, manufacturing and commercialization of potential best-in-class EGFR/HER3 antibody-drug conjugate EGFR and HER3 co-expressed across various solid tumors, i... |
| 20.11.2024 | Avenzo Therapeutics and VelaVigo: A New Chapter in Oncology Innovation | In the fast-paced world of biotechnology, collaboration is the lifeblood of innovation. Avenzo Therapeutics and VelaVigo are prime examples of this synergy. Recently, Avenzo Therapeutics, based in San Diego, secured a significant boost in f... |
| 19.11.2024 | Avenzo Therapeutics Closes Series A/A-1 Financing | Avenzo Therapeutics, a San Diego, CA-based clinical-stage biotechnology company developing new oncology therapies for patients, raised an undisclosed amount in Series A/A1 funding. The prior syndicate of investors, namely OrbiMed, Foresite ... |
| 18.11.2024 | VelaVigo Announces Exclusive Option Agreement with Avenzo to License a Potential First-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate | SHANGHAI and BOSTON, Nov. 18, 2024 /PRNewswire/ -- VelaVigo Cayman Limited (VelaVigo), a biotech company focusing on discovery and development of multi-specific antibodies and antibody-drug conjugates (ADC), today announced it has entered i... |
| 14.05.2024 | Avenzo, BioAge-backer Sands Capital raises new $555M life sciences fund | Sands Capital has raised more than half a billion dollars for a new life science fund, readying a slew of new bets toward therapeutic, diagnostic and device companies. The Arlington, Virginia-based venture investor said Tuesday that the new... |
Show more